Company Encyclopedia
View More
name
GENFIT SPON ADS EACH REP 1 ORD SHS
GNFTY.US
1.930 T
GNFTY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking241/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-51.74%E
    • Profit Margin-85.89%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-42.64%E
    • Net Profit YoY-278.01%E
    • Total Assets YoY21.56%A
    • Net Assets YoY-41.11%E
  • Cash ScoreE
    • Cash Flow Margin-116.42%D
    • OCF YoY-42.64%E
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreE
    • Gearing Ratio75.78%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GENFIT Announces Appointment of new Chief Medical Officer

    GENFIT today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of ...

    GlobeNewswire·
    US
    GNFTY
    -2.23%
    GlobeNewswire·
    US
    GNFTY
    -2.23%

    Genfit Announces Effectiveness Of Delisting Of American Depositary Shares From Nasdaq

    Genfit SA :GENFIT ANNOUNCES EFFECTIVENESS OF VOLUNTARY DELISTING OF AMERICAN DEPOSITARY SHARES FROM NASDAQ STOCK MARKET

    Reuters·
    US
    GNFTY
    -2.23%
    Reuters·
    US
    GNFTY
    -2.23%

    GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

    GENFIT announces the Company's voluntary delisting of American Depositary Shares ("ADSs") representing its ordinary shares from The Nasdaq Global ...

    GlobeNewswire·
    US
    GNFTY
    -2.23%
    US
    GNFT
    0.00%
    GlobeNewswire·
    US
    GNFTY
    -2.23%
    US
    GNFT
    0.00%

    Genfit SA reports €39.2 million revenue for first nine months of 2025

    Genfit SA reported €39.2 million in revenue for the first nine months of 2025, down from €59.7 million in the same period in 2024. The revenue was primarily from a Licensing and Collaboration Agreement with Ipsen. The company had €119.0 million in cash and cash equivalents as of September 30, 2025. Genfit expects its cash position to cover expenses beyond 2028. Key developments include R&D efforts in liver failure and a Phase 1 study of G1090N2. This summary is based on AI-generated content by Public Technologies.

    Reuters·
    US
    GNFTY
    -2.23%
    Reuters·
    US
    GNFTY
    -2.23%

    Genfit SA to Terminate Nasdaq ADS Facility on February 5, 2026

    Genfit SA has announced the voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Global Select Market, effective immediately. The company will terminate its Deposit Agreement with The Bank of New York Mellon on February 6, 2026, ending the ADS facility on February 5, 2026. Investors can exchange their ADSs for underlying ordinary shares or cash, net of fees.

    Reuters·
    US
    GNFTY
    -2.23%
    Reuters·
    US
    GNFTY
    -2.23%
    © 2025 Longbridge｜Disclaimer